[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Elutia Inc (ELUT)

Elutia Inc (ELUT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 38,133
  • Shares Outstanding, K 44,289
  • Annual Sales, $ 12,290 K
  • Annual Income, $ 53,380 K
  • EBIT $ -23 M
  • EBITDA $ -21 M
  • 60-Month Beta 0.88
  • Price/Sales 3.11
  • Price/Cash Flow N/A
  • Price/Book 2.48
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.49
  • Most Recent Earnings $-0.17 on 08/13/26
  • Next Earnings Date 11/05/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.26
  • Growth Rate Est. (year over year) +384,330.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7642 +12.67%
on 08/13/26
1.0510 -18.08%
on 08/27/26
+0.0042 (+0.49%)
since 07/31/26
3-Month
0.7642 +12.67%
on 08/13/26
1.1000 -21.73%
on 06/10/26
-0.1990 (-18.77%)
since 06/01/26
52-Week
0.5000 +72.20%
on 12/17/25
2.3800 -63.82%
on 09/02/25
-1.4190 (-62.24%)
since 08/29/25

Most Recent Stories

More News
Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.

Cellution Biologics acquires SimpliDerm®, expanding its human tissue portfolio and entering the U.S. reconstructive surgery market....

ELUT : 0.8610 (-0.36%)
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 months Divestiture further concentrates Elutia’s attention and...

ELUT : 0.8610 (-0.36%)
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch...

ELUT : 0.8610 (-0.36%)
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results

Independent Blinded Survey of 50 Plastic Surgeons Validates Demand; NXT-41 and NXT-41x Remain On-Track

ELUT : 0.8610 (-0.36%)
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results

Funded through launch:  secured up to $26 million of capital without an equity offering The unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection risk The...

ELUT : 0.8610 (-0.36%)
Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market

$10 million funded at closing; second $5 million tranche unlocked upon FDA 510(k) clearance of NXT-41x Preserves shareholder value by funding commercialization of Elutia's next-generation antibiotic-eluting...

ELUT : 0.8610 (-0.36%)
Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026...

ELUT : 0.8610 (-0.36%)
Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

GAITHERSBURG, Md., July 31, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release...

ELUT : 0.8610 (-0.36%)
Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch

Transaction provides $8 million in cash at closing and up to $3 million in technology transfer and commercial milestone payments over the next 18 months Proceeds provide additional non-dilutive capital...

ELUT : 0.8610 (-0.36%)
Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch

Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch...

ELUT : 0.8610 (-0.36%)

Business Summary

Elutia Inc. develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them. Elutia Inc., formerly known as Aziyo Biologics Inc., is based in SILVER SPRING, Md.

See More

Key Turning Points

3rd Resistance Point 1.0246
2nd Resistance Point 0.9853
1st Resistance Point 0.9231
Last Price 0.8610
1st Support Level 0.8216
2nd Support Level 0.7823
3rd Support Level 0.7201

See More

52-Week High 2.3800
Fibonacci 61.8% 1.6618
Fibonacci 50% 1.4400
Fibonacci 38.2% 1.2182
Last Price 0.8610
52-Week Low 0.5000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.